

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1. (Currently Amended) A pharmaceutical composition comprising an effective amount of loteprednol or a pharmaceutically acceptable ~~tolerable~~ ester thereof and azelastine ~~at least one antihistamine~~.

Claim 2. (Currently Amended) The composition according to claim 1, wherein the azelastine ~~antihistamine~~ is administrable nasally or ocularly.

Claim 3. (Canceled)

Claim 4. (Previously Presented) The composition according to claim 1, wherein the pharmaceutically tolerable ester is loteprednol etabonate.

Claim 5. (Currently Amended) A method for the treatment of one or more allergic disorders selected from the group consisting of allergic rhinitis and allergic conjunctivitis ~~allergic disorders of the lower or upper airways and the eyes~~, comprising administering to a person in need thereof, an effective amount of loteprednol or a pharmaceutically acceptable ester thereof and ~~at least one~~ intranasally or intraocularly administrable azelastine ~~antihistamine~~, optionally

together with customary excipients or vehicles, for simultaneous, sequential or separate administration.

Claim 6. (Canceled)

Claim 7. (Currently Amended) The method according to claim 9 ~~5~~, wherein the loteprednol ~~substance~~ is administered as an inhalable liquid preparation.

Claim 8. (Currently Amended) The method according to claim 9 ~~5~~, wherein the azelastine ~~which~~ is administered orally.

Claim 9. (Currently Amended) A method for the treatment and prophylaxis of one or more allergic disorders selected from the group consisting of allergic rhinitis and allergic conjunctivitis ~~allergic airway and eye disorders~~, comprising administering to a person in need thereof, an effective amount of loteprednol and azelastine ~~at least one intranasally or intraocularly administrable antihistamine~~, wherein the loteprednol or a pharmaceutically acceptable ester thereof and the azelastine ~~is antihistamine(s)~~ are administered simultaneously, sequentially or separately, optionally together with customary excipients or vehicles.

Claim 10. (Canceled)

Claim 11. (Currently Amended) A method for the treatment of one or more allergic disorders selected from the group consisting of allergic rhinitis and allergic

conjunctivitis allergic rhinitis or rhinoconjunctivitis comprising administering to a patient in need thereof, a combination of loteprednol or a pharmaceutically acceptable ester thereof and azelastine ~~an antihistamine~~ for simultaneous, sequential or separate administration.

Claim 12 (New) The composition according to claim 1, wherein the daily dose of loteprednol is between 10 and 500 μg and the daily does of azelastine is between 50 and 500 μg .

Claim 13. (New) The method according to any one of claims 5, 7 or 11, wherein the daily dose of loteprednol is between 10 and 500 μg , and the daily dose of azelastine is between 50 and 500 μg .

Claim 14. (New) The method of claim 12, wherein the daily dose of loteprednol is between 50 and 200 μg and the daily does of azelastine is between 100 and 200 μg .

Claim 15. (New) The method of claim 13, wherein the daily dose of loteprednol is between 50 and 200 μg and the daily does of azelastine is between 100 and 200 μg .